Innate immune response in systemic autoimmune diseases: a potential target of therapy

被引:14
|
作者
Hejrati, Alireza [1 ]
Rafiei, Alireza [2 ]
Soltanshahi, Mohsen [2 ,3 ]
Hosseinzadeh, Shahnaz [2 ,3 ]
Dabiri, Mina [2 ,3 ]
Taghadosi, Mahdi [4 ]
Taghiloo, Saeid [2 ,3 ]
Bashash, Davood [5 ]
Khorshidi, Fatemeh [6 ]
Zafari, Parisa [2 ,3 ]
机构
[1] Hazrat E Rasool Gen Hosp, Dept Internal Med, Tehran, Iran
[2] Mazandaran Univ Med Sci, Sch Med, Dept Immunol, Sari, Iran
[3] Mazandaran Univ Med Sci, Sch Med, Student Res Comm, Sari, Iran
[4] Kermanshah Univ Med Sci, Sch Med, Dept Immunol, Kermanshah, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Hematol & Blood Banking, Tehran, Iran
[6] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Tehran, Iran
关键词
Autoimmunity; Innate immunity; Lupus; Polymyositis; Rheumatoid arthritis; PRIMARY SJOGRENS-SYNDROME; TUMOR-NECROSIS-FACTOR; PLASMACYTOID DENDRITIC CELLS; HUMAN MONOCLONAL-ANTIBODY; NATURAL-KILLER-CELLS; I INTERFERON SYSTEM; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; JAK1-SELECTIVE INHIBITOR; INFLAMMATORY MYOPATHIES;
D O I
10.1007/s10787-020-00762-y
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Innate immunity refers to defense mechanisms that are always present, ready to combat microbes and other offending agents. Innate immunity acts as a first-line defense and activates the conventional immune responses; however, it has been speculated that the importance of innate immunity in initiation and development of some disorders is more than just the "first line of defense". Autoimmune diseases, caused by immune system overactivation, are among the most challenging scientific and clinical problems, and there is still much to be learned about their pathogenesis. We aimed to provide a comprehensive overview of available documents about the role of innate immunity in systemic autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, polymyositis, and systemic sclerosis. This study highlights the innate immunity pathways or molecules that are under investigation for therapy of these diseases.
引用
收藏
页码:1421 / 1438
页数:18
相关论文
共 50 条
  • [11] Complement as a Therapeutic Target in Systemic Autoimmune Diseases
    Galindo-Izquierdo, Maria
    Pablos Alvarez, Jose Luis
    [J]. CELLS, 2021, 10 (01) : 1 - 18
  • [12] TARGET ANTIGENS IN SYSTEMIC AUTOIMMUNE-DISEASES
    NAPARSTEK, Y
    TADMOR, B
    PUTTERMAN, C
    BARTANA, R
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1994, 30 (03): : 31 - 33
  • [13] IMMUNE-RESPONSE POTENTIAL AND ITS GENETIC-REGULATION IN AUTOIMMUNE-DISEASES - ALTERATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS AND THYROID AUTOIMMUNE-DISEASES
    BENTWICH, Z
    SHALEV, Y
    SEGAL, R
    KATZ, D
    MOZES, E
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 475 : 227 - 230
  • [14] Volume therapy and innate immune response during systemic inflammation or sepsis - Reply
    Rivers, Emanuel P.
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (03) : 1028 - 1029
  • [15] OESTROGENS, IMMUNE RESPONSE AND AUTOIMMUNE DISEASES
    Cutolo, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 12 - 12
  • [16] Inflammatory molecules: A target for treatment of systemic autoimmune diseases
    Tincani, A.
    Andreoli, L.
    Bazzani, C.
    Bosisio, D.
    Sozzani, S.
    [J]. AUTOIMMUNITY REVIEWS, 2007, 7 (01) : 1 - 7
  • [17] SYSTEMIC AUTOIMMUNE-DISEASES - POSSIBLE INVOLVEMENT OF SUPERANTIGENS IN THE ABNORMAL IMMUNE-RESPONSE
    NAMBOODIRI, MSA
    [J]. CURRENT SCIENCE, 1993, 64 (04): : 234 - 238
  • [18] Deubiquitylating enzymes: potential target in autoimmune diseases
    Parihar, Niraj
    Bhatt, Lokesh Kumar
    [J]. INFLAMMOPHARMACOLOGY, 2021, 29 (06) : 1683 - 1699
  • [19] Deubiquitylating enzymes: potential target in autoimmune diseases
    Niraj Parihar
    Lokesh Kumar Bhatt
    [J]. Inflammopharmacology, 2021, 29 : 1683 - 1699
  • [20] Potential target of infliximab in autoimmune and inflammatory diseases
    Atzeni, Fabiola
    Doria, Andrea
    Carrabba, Mario
    Turiel, Maurizio
    Sarzi-Puttini, Piercarlo
    [J]. AUTOIMMUNITY REVIEWS, 2007, 6 (08) : 529 - 536